The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 02, 2020

Filed:

Nov. 11, 2016
Applicant:

Hangzhou Solipharma Co., Ltd., Hangzhou, Zhejiang, CN;

Inventors:

Xiaohong Sheng, Zhejiang, CN;

Xiaoxia Sheng, Zhejiang, CN;

Xiawei Jiang, Zhejiang, CN;

Assignee:

Hangzhou SoliPharma Co., Ltd., Hangzhou, Zhejang, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/06 (2006.01); A61K 31/444 (2006.01); A61P 25/06 (2006.01);
U.S. Cl.
CPC ...
C07D 401/06 (2013.01); A61K 31/444 (2013.01); A61P 25/06 (2018.01); C07B 2200/13 (2013.01);
Abstract

The present invention relates to the crystalline forms of a 5-HTreceptor agonist 2,4,6-trifluoro-N-[6-[(1-methyl-piperidine-4-yl)carbonyl]pyridin-2-yl]-benzene formamide (lasmiditan) and its hydrochloride. The crystalline forms of the present invention have advantages in crystallinity, hygroscopicity, morphology, crystal form stability, and chemical stability as compared with the known forms of lasmiditan and lasmiditan hydrochloride. The present invention also relates to processes for the preparation of the crystalline forms of lasmiditan and lasmiditan hydrochloride, pharmaceutical compositions thereof and their use in treating and/or preventing a patient's migraine and other diseases or conditions associated with 5-HTreceptor dysfunction.


Find Patent Forward Citations

Loading…